Targeting FOXM1 condensates reduces breast tumour growth and metastasis

Feng Xie (), Xiaoxue Zhou, Yu Ran, Ran Li, Jing Zou, Shiyun Wan, Peng Su, Xuli Meng, Haiyan Yan, Huasong Lu, Heng Ru, Hai Hu, Zhengwei Mao (), Bing Yang (), Fangfang Zhou () and Long Zhang ()
Additional contact information
Feng Xie: Soochow University
Xiaoxue Zhou: School of Medicine, Hangzhou City University
Yu Ran: Zhejiang University
Ran Li: School of Medicine, Hangzhou City University
Jing Zou: Zhejiang University
Shiyun Wan: Soochow University
Peng Su: Hangzhou Medical College
Xuli Meng: Hangzhou Medical College
Haiyan Yan: School of Medicine, Hangzhou City University
Huasong Lu: Zhejiang University
Heng Ru: Zhejiang University
Hai Hu: Chinese Academy of Sciences
Zhengwei Mao: Zhejiang University
Bing Yang: Zhejiang University
Fangfang Zhou: Soochow University
Long Zhang: Tianfu Jincheng Laboratory

Nature, 2025, vol. 638, issue 8052, 1112-1121

Abstract: Abstract Identifying phase-separated structures remains challenging, and effective intervention methods are currently lacking1. Here we screened for phase-separated proteins in breast tumour cells and identified forkhead (FKH) box protein M1 (FOXM1) as the most prominent candidate. Oncogenic FOXM1 underwent liquid–liquid phase separation (LLPS) with FKH consensus DNA element, and compartmentalized the transcription apparatus in the nucleus, thereby sustaining chromatin accessibility and super-enhancer landscapes crucial for tumour metastatic outgrowth. Screening an epigenetics compound library identified AMPK agonists as suppressors of FOXM1 condensation. AMPK phosphorylated FOXM1 in the intrinsically disordered region (IDR), perturbing condensates, reducing oncogenic transcription, accumulating double-stranded DNA to stimulate innate immune responses, and endowing discrete FOXM1 with the ability to activate immunogenicity-related gene expressions. By developing a genetic code-expansion orthogonal system, we demonstrated that a phosphoryl moiety at a specific IDR1 site causes electrostatic repulsion, thereby abolishing FOXM1 LLPS and aggregation. A peptide targeting IDR1 and carrying the AMPK-phosphorylated residue was designed to disrupt FOXM1 LLPS and was shown to inhibit tumour malignancy, rescue tumour immunogenicity and improve tumour immunotherapy. Together, these findings provide novel and in-depth insights on function and mechanism of FOXM1 and develop methodologies that hold promising implications in clinics.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41586-024-08421-w Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:638:y:2025:i:8052:d:10.1038_s41586-024-08421-w

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-024-08421-w

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().